Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer

Gynecologic Oncology
David E CohnJeffrey M Fowler

Abstract

To determine the ability of patients to be treated with biweekly bevacizumab and weekly taxane chemotherapy in women with advanced, refractory ovarian cancer. Ten patients with advanced, recurrent, and refractory ovarian cancer who were treated with biweekly bevacizumab (10 mg/kg) and weekly taxane (paclitaxel or docetaxel) chemotherapy days 1, 8, 15, and 22 every 28 days were identified retrospectively. All patients were followed with serial CA125 measurements prior to each cycle of therapy; cross-sectional imaging was not used to follow response to therapy. Toxicities were assessed prior to each cycle of treatment. Of the 10 patients treated with weekly taxane and biweekly bevacizumab therapy, all 9 that were evaluable had a decrease in CA125. Five patients have had an increase in CA125 after therapy after a median of three cycles (range 1-4), while 3 patients experienced normalization of CA125 and another with continued improvement in CA125. All symptomatic patients experienced rapid palliation of pain, nausea, and ascites. Side effects have been mild, with no grade 3 or 4 toxicities noted. No treatment delays or discontinuations have been necessary. Treatment of advanced, recurrent, refractory epithelial ovarian cancer with...Continue Reading

References

Apr 20, 2000·The Journal of Clinical Investigation·D HanahanE Bergsland
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maurie MarkmanMark Baker
Oct 3, 2002·Nature Reviews. Cancer·Robert Kerbel, Judah Folkman
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz KabbinavarEmily Bergsland
Feb 22, 2005·Gynecologic Oncology·Bradley J MonkRobert A Burger

❮ Previous
Next ❯

Citations

Jan 12, 2012·Clinical & Developmental Immunology·Filippo BellatiMarianna Nuti
Mar 6, 2008·Cancer Chemotherapy and Pharmacology·Laura Q M ChowS Gail Eckhardt
Jan 15, 2010·Journal of Oncology·Francois P Duhoux, Jean-Pascal Machiels
Sep 25, 2009·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Alfonso Sánchez-MuñozAntonio González-Martín
Jul 13, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A JaishuenJ J Kavanagh
Jul 25, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·J D WrightD G Mutch
Dec 30, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M Markman
Feb 14, 2008·Expert Opinion on Therapeutic Targets·J Reibenwein, M Krainer
Dec 4, 2009·Expert Review of Anticancer Therapy·Federica TomaoSilverio Tomao
Dec 22, 2007·Expert Review of Anticancer Therapy·Fiona J CollinsonGordon C Jayson
Oct 20, 2007·Expert Review of Anticancer Therapy·Ernest S Han, Bradley J Monk
Oct 12, 2007·Expert Opinion on Pharmacotherapy·Susan C Modesitt, Amir A Jazaeri
Jul 25, 2015·Expert Opinion on Investigational Drugs·Claudia MarchettiPierluigi Benedetti Panici
Sep 4, 2008·Expert Opinion on Emerging Drugs·Toru Sugiyama, Ikuo Konishi
Aug 13, 2009·Expert Opinion on Pharmacotherapy·Maurie Markman
Oct 24, 2013·Systems Biology in Reproductive Medicine·Batoul Y AbdallahHenry H Q Heng
Nov 8, 2011·Critical Reviews in Oncology/hematology·Filippo BellatiMarianna Nuti
Feb 24, 2009·Gynecologic Oncology·Peter J FrederickDonald J Buchsbaum
Oct 3, 2008·Gynecologic Oncology·Debra L RichardsonLarry J Copeland
Mar 18, 2008·Critical Reviews in Oncology/hematology·Phuong DinhAhmad Awada
Apr 1, 2009·Seminars in Oncology·Lainie P Martin, Russell J Schilder
May 22, 2007·Seminars in Oncology·Ronald M BukowskiMaurie Markman
Oct 13, 2006·Gynecologic Oncology·Kathleen M Darcy, Russel J Schilder
Jul 19, 2006·Gynecologic Oncology·Carol Aghajanian
Jan 4, 2007·The American Journal of Pathology·Balázs DömeJózsef Tímár
Feb 10, 2007·Gynecologic Oncology·Stephan PolterauerLukas A Hefler
Mar 12, 2013·Medical Hypotheses·Laura Elise HorvathKimberly Jones
Nov 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert A BurgerJoel I Sorosky
Jul 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert A Burger
Jul 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lainie Martin, Russell Schilder
May 4, 2013·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Floor J BackesDavid M O'Malley
Feb 13, 2008·Nature Clinical Practice. Oncology·Whitney A SpannuthRobert L Coleman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.